Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: A phase II randomized clinical trial

Vaccine

Volumn 32, Issue 25, 2014, Pages 3025-3034

  Prymula, Roman ^a   Pazdiora, Petr ^b   Traskine, Magali ^c   Rüggeberg, Jens U ^c   Borys, Dorota ^c  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c GSK   (Belgium)

Author keywords

DPly; Immunogenicity; PhtD; Pneumococcal proteins; Safety; Toddler vaccination

Indexed keywords

PNEUMOCOCCAL HISTIDINE TRIAD PROTEIN VACCINE; PNEUMOCOCCAL NON TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE; PNEUMOCOCCAL PNEUMOLYSIN TOXOID VACCINE; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ARTICLE; CHILD; CONTROLLED STUDY; COUGHING; CZECH REPUBLIC; DRUG CONJUGATION; DRUG SAFETY; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE FIBROSIS; INJECTION SITE PAIN; INSOMNIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONTYPEABLE HAEMOPHILUS INFLUENZAE; PHASE 2 CLINICAL TRIAL; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; SWELLING; TODDLER; VACCINATION; VOMITING;

DPLY; IMMUNOGENICITY; PHTD; PNEUMOCOCCAL PROTEINS; SAFETY; TODDLER VACCINATION;

ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CZECH REPUBLIC; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; HYDROLASES; IMMUNIZATION, SECONDARY; INFANT; MALE; PNEUMOCOCCAL VACCINES; STREPTOLYSINS; VACCINES, CONJUGATE;

EID: 84899994434     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.03.066     Document Type: Article

References (32)

1. Lynch J.P., Zhanel G.G. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med 2010, 16(3):217-225.
2. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374(9693):893-902.
3. Grijalva C.G., Nuorti J.P., Arbogast P.G., Martin S.W., Edwards K.M., Griffin M.R. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007, 369(9568):1179-1186.
4. Crisinel P.A., Chevalier I., Rallu F., Tapiero B., Lamarre V., Thibault R., et al. Invasive pneumococcal disease after implementation of a reduced three-dose pneumococcal conjugate vaccine program: a pediatric tertiary care center experience. Eur J Pediatr 2010, 169(11):1311-1315.
5. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(1):32-41.
6. Weinberger D.M., Malley R., Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011, 378(9807):1962-1973.
7. Kaplan S.L., Barson W.J., Lin P.L., Stovall S.H., Bradley J.S., Tan T.Q., et al. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics 2010, 125(3):429-436.
8. Beall B., McEllistrem M.C., Gertz R.E., Wedel S., Boxrud D.J., Gonzalez A.L., et al. Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol 2006, 44(3):999-1017.
9. Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae-Massachusetts, 2001-2006. MMWR Morb Mortal Wkly Rep 2007, 56(41):1077-1080.
10. Lee G.M., Kleinman K., Pelton S.I., Hanage W., Huang S.S., Lakoma M., et al. Impact of 13-valent pneumococcal conjugate vaccination on Streptococcus pneumoniae carriage in young children in Massachusetts. J Pediat Infect Dis Soc 2013.
11. Demczuk W.H., Martin I., Griffith A., Lefebvre B., McGeer A., Shane A., et al. Serotype distribution of invasive Streptococcus pneumoniae in Canada during the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. Can J Microbiol 2012, 58(8):1008-1017.
12. Kaplan S.L., Barson W.J., Lin P.L., Romero J.R., Bradley J.S., Tan T.Q., et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013, 32(3):203-207.
13. Pichichero M.E., Kaur R., Casey J.R., Xu Q., Almudevar A., Ochs M. Antibody response to Streptococcus pneumoniae proteins PhtD, LytB, PcpA, PhtE and Ply after nasopharyngeal colonization and acute otitis media in children. Hum Vaccin Immunother 2012, 8(6):799-805.
14. Alexander J.E., Lock R.A., Peeters C.C., Poolman J.T., Andrew P.W., Mitchell T.J., et al. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun 1994, 62(12):5683-5688.
15. Ogunniyi A.D., Woodrow M.C., Poolman J.T., Paton J.C. Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. Infect Immun 2001, 69(10):5997-6003.
16. Garcia-Suarez M.M., Cima-Cabal M.D., Florez N., Garcia P., Cernuda-Cernuda R., Astudillo A., et al. Protection against pneumococcal pneumonia in mice by monoclonal antibodies to pneumolysin. Infect Immun 2004, 72(8):4534-4540.
17. Godfroid F., Hermand P., Verlant V., Denoel P., Poolman J.T. Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens. Infect Immun 2011, 79(1):238-245.
18. Denoel P., Philipp M.T., Doyle L., Martin D., Carletti G., Poolman J.T. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae. Vaccine 2011, 29(33):5495-5501.
19. Leroux-Roels G, Maes C, De Boever F, Traskine M, Rüggeberg JU, Borys D. Safety/reactogenicity results of a phase I clinical trial of an investigational pneumococcal protein-based vaccine in adults. 8th ISPPD meeting; 2012.
20. Prymula R., Schuerman L. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev Vaccines 2009, 8(11):1479-1500.
21. Findlay J.W., Smith W.C., Lee J.W., Nordblom G.D., Das I., DeSilva B.S., et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal 2000, 21(6):1249-1273.
22. Poolman J.T., Frasch C.E., Kayhty H., Lestrate P., Madhi S.A., Henckaerts I. Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol 2010, 17(1):134-142.
23. Henckaerts I., Durant N., De G.D., Schuerman L., Poolman J. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine 2007, 25(13):2518-2527.
24. Seiberling M., Bologa M., Brookes R., Ochs M., Go K., Neveu D., et al. Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults. Vaccine 2012, 30(52):7455-7460.
25. Bologa M., Kamtchoua T., Hopfer R., Sheng X., Hicks B., Bixler G., et al. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine. Vaccine 2012, 30(52):7461-7468.
26. Kamtchoua T., Bologa M., Hopfer R., Neveu D., Hu B., Sheng X., et al. Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults. Vaccine 2013, 31(2):327-333.
27. Sharma S.K., Roumanes D., Almudevar A., Mosmann T.R., Pichichero M.E. CD4 T-cell responses among adults and young children in response to Streptococcus pneumoniae and Haemophilus influenzae vaccine candidate protein antigens. Vaccine 2013, 31(30):3090-3097.
28. Rapola S., Jantti V., Haikala R., Syrjanen R., Carlone G.M., Sampson J.S., et al. Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J Infect Dis 2000, 182(4):1146-1152.
29. Holmlund E., Quiambao B., Ollgren J., Jaakkola T., Neyt C., Poolman J., et al. Antibodies to pneumococcal proteins PhtD, CbpA, and LytC in Filipino pregnant women and their infants in relation to pneumococcal carriage. Clin Vaccine Immunol 2009, 16(6):916-923.
30. Holmlund E., Quiambao B., Ollgren J., Nohynek H., Kayhty H. Development of natural antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A and pneumolysin in Filipino pregnant women and their infants in relation to pneumococcal carriage. Vaccine 2006, 24(1):57-65.
31. Prymula R., Peeters P., Chrobok V., Kriz P., Novakova E., Kaliskova E., et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006, 367(9512):740-748.
32. Ginsburg A.S., Nahm M.H., Khambaty F.M., Alderson M.R. Issues and challenges in the development of pneumococcal protein vaccines. Expert Rev Vaccines 2012, 11(3):279-285.